Emeramed has discontinued our early access program in most of the world
to focus our efforts on bringing Irminix® to market as soon as possible.

Early Access is ONLY available in New Zealand and Lebanon,
before sending inquiries please read this information

Additionally, Irminix® has not been approved for pediatric use

.

Get in touch

Ireland

Sweden

United States

Contact Us:

The scientific literature has firmly established that mercury causes a biochemical train wreck especially in the brain where it is linked to a host of neurological illnesses and oxidative stress.

Boyd Haley, PhD, Chief Scientist and CEO

About

Learn about our company, mission and board of directors.

Early Access

Irminix® has been approved for compassionate use.

Information

Latest News, Research, Clinical Trials, Press and Newsletters.

Investors

Investor Information about EmeraMed Ltd.

Discover The Future of Health

We are committed to improving health by way of our unique metal chelator and antioxidant, Irminix®

Contact Us